Your browser doesn't support javascript.
loading
Access to Medications for Opioid Use Disorder for Persons With Human Immunodeficiency Virus in the United States: Gaps in Coverage by State AIDS Drug Assistance Programs.
McManus, Kathleen A; Davy-Mendez, Thibaut; Killelea, Amy; Schranz, Asher J.
Affiliation
  • McManus KA; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA.
  • Davy-Mendez T; Division of Infectious Diseases, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Killelea A; Killelea Consulting, Arlington, Virginia, USA.
  • Schranz AJ; Division of Infectious Diseases, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Open Forum Infect Dis ; 9(4): ofac057, 2022 Apr.
Article in En | MEDLINE | ID: mdl-35265727
Life-saving medications for opioid use disorder are inaccessible for people with human immunodeficiency virus relying on the AIDS Drug Assistance Programs (ADAP) in 40% of jurisdictions. Funding/policies should address this through increasing access through ADAP and the Ryan White HIV/AIDS Program (RWHAP), partnerships between RWHAP and substance use programs, and other state/federal initiatives.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Open Forum Infect Dis Year: 2022 Document type: Article Affiliation country: United States Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Open Forum Infect Dis Year: 2022 Document type: Article Affiliation country: United States Country of publication: United States